Head-to-head · WeighScore
Tablet Health vs Vytora Health
The verdict
Vytora Health takes it — 72.3/100 to 47.6/100.
Vytora Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vytora Health is a 50-state-plus-DC telehealth platform offering compounded semaglutide and tirzepatide alongside brand-name Mounjaro and Zepbound, plus NAD+ and sermorelin peptides.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Tablet Health | Vytora Health |
|---|---|---|
| WeighScore | 47.6/100 | 72.3/100 |
| Grade | C | C |
| Scorecard rank | #495 | #79 |
| Semaglutide | Not disclosed | $180/mo (all doses, compounded) |
| Tirzepatide | Not disclosed | $249/mo (all doses, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Graded #79 · C
Strengths
- All 50 states plus DC, with per-state video-vs-audio compliance disclosed
- Both compounded and brand-name options on one platform — uncommon
- LegitScript Approved and HIPAA compliant
- Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
- Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)
Where it loses points
- Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
- Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
- Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
- Initial consultation cost not shown on the public pricing page
- Limited per-prescriber state licensure detail
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.